Vogenx announces positive results from second phase 2 study of mizagliflozin in post-bariatric hypoglycaemia
Vogenx has announced positive results from study VGX 001-012 evaluating mizagliflozin in patients diagnosed with post-bariatric...
top of page
Browse by category
Search
Last patient receives Mizagliflozin in Phase 2 clinical study for the treatment of post-bariatric hypoglycaemia
Vogenx has completed dosing of the last patient in its Phase 2 clinical study VGX-001-012 evaluating Mizagliflozin in patients diagnosed...
Enrolment complete in Vogenx’ Phase 2 Trial of mizagliflozin for post-bariatric hypoglycaemia
Vogenx has completed patient enrolment of a mid-Phase 2 clinical dose ranging study (VGX-001-012) evaluating mizagliflozin in patients...
Positive results for mizagliflozin in post-bariatric hypoglyceamia patients
Vogenx has announced positive results from its VGX 001-011 study, a phase 2 multi-centre, randomised, sequential crossover, single...
Browse by tag
bottom of page